File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion

TitleA randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion
Authors
Issue Date2009
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2009, v. 24 n. 2, p. 320-324 How to Cite?
AbstractBACKGROUND: The conventional timing of misoprostol administration after mifepristone for second trimester medical abortion is 36-48 h, but simultaneous administration, which may make the regimen more convenient, has not been studied. The objective of this randomized comparison study is to compare two intervals of administration of misoprostol after pretreatment with mifepristone for second trimester medical abortion. METHODS: Eligible women with gestational age between 12 and 20 weeks were randomized to receive mifepristone 200 mg orally followed by 600 μg misoprostol vaginally either immediately or 36-38 h later, followed by 400 μg vaginal misoprostol every 3 h for a maximum of four doses. The primary outcome measure was the success rate at 24 h after the start of misoprostol treatment and the secondary outcome measures were the induction-to-abortion interval and the frequency of side effects. RESULTS: There was a significant difference in the success rate at 24 h (36-38 h: 100%; immediate: 91.5%). The median induction-to-abortion interval was significantly shorter in the 36-38 h regimen (4.9 h) compared with the immediate regimen (10 h). Side effects in terms of febrile episodes and chills/rigors were significantly higher in the immediate administration group. CONCLUSIONS: Simultaneous use of mifepristone and misoprostol for second trimester medical abortion is not as effective as the regimen using a 36-38 h dosing interval. © The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/173342
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChai, Jen_US
dc.contributor.authorTang, OSen_US
dc.contributor.authorHong, QQen_US
dc.contributor.authorChen, QFen_US
dc.contributor.authorCheng, LNen_US
dc.contributor.authorNg, Een_US
dc.contributor.authorHo, PCen_US
dc.date.accessioned2012-10-30T06:29:30Z-
dc.date.available2012-10-30T06:29:30Z-
dc.date.issued2009en_US
dc.identifier.citationHuman Reproduction, 2009, v. 24 n. 2, p. 320-324en_US
dc.identifier.issn0268-1161en_US
dc.identifier.urihttp://hdl.handle.net/10722/173342-
dc.description.abstractBACKGROUND: The conventional timing of misoprostol administration after mifepristone for second trimester medical abortion is 36-48 h, but simultaneous administration, which may make the regimen more convenient, has not been studied. The objective of this randomized comparison study is to compare two intervals of administration of misoprostol after pretreatment with mifepristone for second trimester medical abortion. METHODS: Eligible women with gestational age between 12 and 20 weeks were randomized to receive mifepristone 200 mg orally followed by 600 μg misoprostol vaginally either immediately or 36-38 h later, followed by 400 μg vaginal misoprostol every 3 h for a maximum of four doses. The primary outcome measure was the success rate at 24 h after the start of misoprostol treatment and the secondary outcome measures were the induction-to-abortion interval and the frequency of side effects. RESULTS: There was a significant difference in the success rate at 24 h (36-38 h: 100%; immediate: 91.5%). The median induction-to-abortion interval was significantly shorter in the 36-38 h regimen (4.9 h) compared with the immediate regimen (10 h). Side effects in terms of febrile episodes and chills/rigors were significantly higher in the immediate administration group. CONCLUSIONS: Simultaneous use of mifepristone and misoprostol for second trimester medical abortion is not as effective as the regimen using a 36-38 h dosing interval. © The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_US
dc.relation.ispartofHuman Reproductionen_US
dc.rightsHuman Reproduction. Copyright © Oxford University Press.-
dc.subject.meshAbortifacient Agents, Nonsteroidal - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshAbortifacient Agents, Steroidal - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshAbortion, Induceden_US
dc.subject.meshAdulten_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshMisoprostol - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Trimester, Seconden_US
dc.subject.meshTime Factorsen_US
dc.titleA randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortionen_US
dc.typeArticleen_US
dc.identifier.emailChai, J:jchai@hkucc.hku.hken_US
dc.identifier.emailNg, E:nghye@hkucc.hku.hken_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityChai, J=rp00241en_US
dc.identifier.authorityNg, E=rp00426en_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/humrep/den425en_US
dc.identifier.pmid19049993-
dc.identifier.scopuseid_2-s2.0-58449123886en_US
dc.identifier.hkuros156040-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58449123886&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume24en_US
dc.identifier.issue2en_US
dc.identifier.spage320en_US
dc.identifier.epage324en_US
dc.identifier.eissn1460-2350-
dc.identifier.isiWOS:000262519500010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridChai, J=35200414100en_US
dc.identifier.scopusauthoridTang, OS=7006723402en_US
dc.identifier.scopusauthoridHong, QQ=35200780600en_US
dc.identifier.scopusauthoridChen, QF=35738573300en_US
dc.identifier.scopusauthoridCheng, LN=34869443100en_US
dc.identifier.scopusauthoridNg, E=35238184300en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats